NASDAQ · Biotechnology

GYRE (GYRE) Stock

$6.67 +4.22% NASDAQ: GYRE Healthcare

Valuation

MetricValue
Price$6.67
Market Cap$609.58M
P/E Ratio291.50
P/B Ratio5.26
P/S Ratio4.83
EPS (TTM)$0.02
52-Week High$9.42
52-Week Low$5.44
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-3.08%
ROA1.03%
ROCE7.75%
Gross Margin95.09%
Operating Margin-0.12%
Net Margin-5.37%
Debt/Equity0.01
Current Ratio5.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.0M$102.0M$113.0M$106.0M$117.0M
Operating Profit$-84.0M$9.0M$-67.0M$16.0M$11.0M
Net Profit$-88.0M$2.0M$-93.0M$12.0M$5.0M
EPS$-2.87$0.03$-1.41$0.05$0.02
Op Margin-1141.0%9.0%-59.3%15.3%9.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$56.0M$85.0M$117.0M$125.0M$166.0M
Total Liabilities$15.0M$13.0M$103.0M$27.0M$24.0M
Cash$44.0M$25.0M$34.0M$12.0M$37.0M
Borrowings$2.0M$1.0M$0$2.0M$1.0M

Latest News

Gyre Therapeutics Appoints Three New Members to its Board of Directors GlobeNewswire · Jul 16, 2026 US High Growth Tech Stocks To Watch Simply Wall St. · May 28, 2026 New Strong Sell Stocks for May 27th Zacks · May 27, 2026 Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug MT Newswires · May 12, 2026 Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment GlobeNewswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-84.0M$11.0M$26.0M$-4.0M$1.0M
Investing Cash Flow$47.0M$-19.0M$-28.0M$-23.0M$-2.0M
Financing Cash Flow$7.0M$0$0$1.0M$-1.0M
Net Cash Flow$14.0M$-5.0M$8.0M$-22.0M$25.0M
Free Cash Flow$-85.0M$6.0M$17.0M$-7.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA104.18
FCF Yield0.54%
Quick Ratio4.06
Interest Coverage—
Return 1Y-20.61%
Return 3Y-2.28%
Return 5Y-38.45%

Ownership

Insiders Held86.33%
Institutions Held3.76%
Institutions Float Held27.51%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC984,2042026-03-31
Blackrock Inc.758,6302026-03-31
Geode Capital Management, LLC431,4142026-03-31
State Street Corporation216,3262026-03-31
SBI Securities Co., Ltd.170,8372026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATXSAstria Therapeutics, Inc. $12.58 +0.00% -7.40 $718.13M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
AVXL $2.49 -3.11% -5.02 $230.75M 0.00%
CTMX $3.37 +4.01% -24.27 $541.98M 0.00%
ERAS $17.72 -2.42% -23.45 $6.15B 0.00%

About GYRE

GYRE is led by CEO Ping Zhang, employs 579 people, headquartered in US, publicly traded since 2006.

GYRE stock trades at $6.67 with a market capitalization of $609.58M. The stock is valued at a price-to-earnings (P/E) ratio of 291.50, price-to-book of 5.26, price-to-sales of 4.83. Over the past 52 weeks the stock has ranged between $5.44 and $9.42, and currently trades 29.2% below its 52-week high.

On profitability, GYRE generates a return on equity (ROE) of -3.08%, return on capital employed of 7.75%, an operating margin of -0.12%, a net profit margin of -5.37%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides